Skip to main content

Table 1 Comparison between MHT users and non-users

From: The effect of menopausal hormone therapy on gastrointestinal cancer risk and mortality in South Korea: a population-based cohort study

Characteristic

Total (n = 133,690)

MHT

P

Yes (n = 22,577)

No (n = 111,113)

Follow-up months, mean (SD)

74.6 (36.8)

74.4 (36.9)

74.7 (36.7)

0.2916

Age (years)

n

%

n

%

n

%

0.9745

 40–49

65,008

48.63

10,959

48.54

54,049

48.64

 

 50–59

50,866

38.05

8590

38.05

42,276

38.05

 

 60–69

12,902

9.65

2189

9.70

10,713

9.64

 

 70~

4914

3.68

839

3.72

4075

3.67

 

Income level

0.4772

 ≤ 30% (low)

38,082

28.49

6425

28.46

31,657

28.49

 

 31–60%

38,390

28.72

6575

29.12

31,815

28.63

 

 61–90%

33,180

24.82

5555

24.60

27,625

24.86

 

 ≥ 91% (high)

24,038

17.98

4022

17.81

20,016

18.01

 

Region

0.7807

 Metropolitan

63,621

47.59

10,725

47.50

52,896

47.61

 

 Others

70,069

52.41

11,852

52.50

58,217

52.39

 

CCI

< .0001

 1

45,068

33.71

8040

35.61

37,028

33.32

 

 2

39,650

29.66

7364

32.62

32,286

29.06

 

 3

15,894

11.89

2994

13.26

12,900

11.61

 

 4 or more

33,078

24.74

4179

18.51

28,899

26.01

 

Year of study entry

0.9954

 2004

19,707

14.74

3293

14.59

16,414

14.77

 

 2005

18,744

14.02

3142

13.92

15,602

14.04

 

 2006

16,350

12.23

2750

12.18

13,600

12.24

 

 2007

17,018

12.73

2871

12.72

14,147

12.73

 

 2008

14,815

11.08

2507

11.10

12,308

11.08

 

 2009

10,375

7.76

1754

7.77

8621

7.76

 

 2010

11,128

8.32

1891

8.38

9237

8.31

 

 2011

8076

6.04

1374

6.09

6702

6.03

 

 2012

9489

7.10

1623

7.19

7866

7.08

 

 2013

7988

5.98

1372

6.08

7866

5.95

 
  1. CCI Charlson comorbidity index, MHT menopausal hormone therapy, SD standard deviation